Skip to main content

Advertisement

Table 3 Adverse events causally related to treatment (at least possible) reported in at least 2% in any subgroup of patients (sorted by percentages in the 'All patients' group).

From: Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?

Age 6-12 years N = 583 13-18 years N = 239 All patients N = 822
Adverse event (AE) [preferred term] n % n % n %
Patients with at least one AE* 149 25.56 46 19.25 195 23.72
Insomnia 48 8.23 11 4.60 59 7.18
Anorexia 31 5.32 4 1.67 35 4.26
Muscle contractions involuntary 29 4.97 5 2.09 34 4.14
Medicine ineffective 13 2.23 5 2.09 18 2.19
Nervousness 13 2.23 4 1.67 17 2.07
Headache 10 1.72 5 2.09 15 1.82
Concentration impaired 7 1.20 7 2.93 14 1.70
Aggressive reaction 8 1.37 5 2.09 13 1.58
Abdominal pain 12 2.06 0 0.00 12 1.46
Weight decrease 4 0.69 6 2.51 10 1.22
  1. * Chi2- Test: p = 0.066; some patients had more than one AE.